

Special Issue

The Gaseous Neurotransmitter Nitric Oxide: A Potential Therapeutic Target for Neuropsychiatric and Neurodegenerative Disorders

Message from the Guest Editor

The search of novel molecules in therapy is a hot issue. The gaseous neurotransmitter nitric oxide is intensively studied for its implication in a wide range of neuropsychiatric and neurodegenerative diseases, including anxiety, depression, schizophrenia, dementia, Parkinson disease, Alzheimer's disease, etc. This Special Issue of *Molecules* aims to assess new advances of the therapeutic action of nitric oxide and its modulators targeting different pathologies. In this context, we intend to highlight and emphasize their pharmacological activity. We cordially invite researchers working in the field to contribute original research articles, as well as critical review articles, that unravel the therapeutic potential of nitric oxide and its modulators. We look forward to receiving your contributions.

Guest Editor

Prof. Dr. Nikolaos Pitsikas

Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Thessaly, Larisa, Greece

Deadline for manuscript submissions

closed (31 December 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/149333

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).